Overactive bladder in males

Dmochowski, Roger R.; Gomelsky, Alex

doi:10.1177/1756287209350383

Cited by 21 publications

(10 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12 At the molecular physiological level bladder wall thickening can be due to excessive extracellular matrix production and deposition, detrusor cellular growth, hyperplasia and hypertrophy, as well as increased inflammatory responses. 13,25,26 Type I collagen, one of the main constitutive proteins contributing to bladder hypertrophy, is regulated at least in part by increased endogenous NGF in the bladder during cystitis. 13 This study shows that NMDAR activation also contributes to type I collagen up-regulation in the bladder during cystitis.…”

Section: Discussionmentioning

confidence: 99%

Inhibition of NMDAR Reduces Bladder Hypertrophy and Improves Bladder Function in Cyclophosphamide Induced Cystitis

et al. 2015

View full text Add to dashboard Cite

Purpose We examined the role of NMDAR in the regulation of bladder hypertrophy and function in a rat model of cyclophosphamide induced cystitis. Materials and Methods Cystitis was induced by intraperitoneal injection of cyclophosphamide (150 mg/kg body weight). NMDAR phosphorylation (activity) and signal transduction pathways were examined by direct measurement and by specific inhibitors in vivo. Bladder hypertrophy was measured by bladder weight/body weight and type I collagen expression. Bladder function was examined by metabolic recording, conscious cystometry and detrusor muscle strip contractility in response to carbachol. Results NMDAR activity measured by the phosphorylation level of the NMDAR1 (NR1) subunit was expressed in the spinal cord but not in the bladder at 48 hours of cystitis. NMDAR inhibition with dizocilpine (MK-801) reduced the cystitis induced increment of bladder weight and type I collagen up-regulation in the bladder. NMDAR regulated type I collagen up-regulation was mediated by the PI3K/Akt pathway. NMDAR inhibition also attenuated cystitis induced urinary frequency measured by metabolic cage and cystometry. Cystitis decreased the responsiveness of detrusor muscle strips to carbachol, which was reversed by MK-801 in vivo. Unlike MK-801 the NMDAR antagonist D-AP5, which could not block central NMDAR activity, had no effect on bladder hypertrophy, type I collagen up-regulation or Akt activation caused by cystitis in the bladder. Conclusions Findings suggest that NMDAR activity has a role in cystitis induced bladder hypertrophy and overactivity. NMDAR mediated Akt activation may underlie the mechanism of bladder dysfunction.

show abstract

Section: Discussionmentioning

confidence: 99%

Inhibition of NMDAR Reduces Bladder Hypertrophy and Improves Bladder Function in Cyclophosphamide Induced Cystitis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Dmochowski and Gomelsky [ 9 ] suggested that CP/CPPS was another condition with prominent LUTS. The condition is typically accompanied by pain with ejaculation or in the perineal area.…”

Section: Discussionmentioning

confidence: 99%

“…Because there is no gold standard diagnostic test for CP/CPPS and because its etiology is largely unknown, this entity remains a diagnosis of exclusion. As with BPH, the symptoms of CP/CPPS can be present during the storage phase, can be present during the voiding phase, or can occur postmicturition [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Anticholinergics for Chronic Prostatitis/Chronic Pelvic Pain Syndrome in Young and Middle-Aged Patients: A Single-Blinded, Prospective, Multi-Center Study

et al. 2011

View full text Add to dashboard Cite

PurposeChronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) exhibits variable lower urinary tract symptoms (LUTS). The aim of this study was to evaluate the incidence of LUTS and the efficacy of an anticholinergic agent in young and middle-aged CP/CPPS patients.MethodsNinety-six men with CP/CPPS were randomly assigned in a single-blind fashion and received either ciprofloxacin (group 1, 49 patients) or ciprofloxacin and solifenacin (5 mg/day; group 2, 47 patients) for 8 weeks. The National Institutes of Health chronic prostatitis symptom index (NIH-CPSI), the International Prostate Symptom Score (IPSS), and the International Index of Erectile Function-5 (IIEF-5) were used to grade the patients' symptoms and the quality of life impact at the start of the study, and at 4 and 8 weeks from the initiation of the study.ResultsThere was no significant difference between groups 1 and 2 with respect to age, duration of disease, or sub-domains of the IPSS, NIH-CPSI, or IIEF-5 at baseline. Of these patients, 67.4% had LUTS. Statistically significant differences were determined via the NIH-CPSI for total score and the pain and urinary domain scores. Statistically significant differences were determined via the IPSS for total score and the storage domain score. The total score of the IIEF-5 increased, but the change was not significant. There was no statistically significant difference in residual urine.ConclusionsMany CP/CPPS patients had LUTS. Solifenacin in CP/CPPS demonstrated improvements in the NIH-CPSI and the IPSS total score and storage score. Storage factors significantly improved via the NIH-CPSI and IPSS assessments in the solifenacin treatment group.

show abstract

“…Alpha receptor antagonists decrease smooth muscle tone in the prostate and bladder neck [ 14 ]. Because LUTS in men have traditionally been attributed to BPH and obstructed urinary flow, pharmacological therapies have been aimed at improving urinary flow rates rapidly and optimizing voiding efficiency [ 15 ]. According to the European Association of Urology guidelines, alpha-blockers should be offered to men with moderate to severe LUTS and are considered the first-line drug treatment for these patients [ 16 ].…”

Section: Alpha Receptor Antagonistsmentioning

confidence: 99%

Current role of treatment in men with lower urinary tract symptoms combined with overactive bladder

Lee

2014

Prostate International

View full text Add to dashboard Cite

Lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) are highly prevalent in older men. The storage subcategory of LUTS is synonymous with overactive bladder (OAB) syndrome, which is an empirical diagnosis. Traditionally, alpha-blockers are widely prescribed to manage the LUTS of BPH, although storage symptoms may persist in many men despite treatment. Therefore, because therapies that target the prostate often fail to alleviate storage symptoms, they may not be the appropriate therapy for OAB. In past years, most physicians appeared to give more weight in elderly men to voiding symptoms than to storage symptoms and to be more concerned with initial treatment with anticholinergics for males with storage symptoms. Considering the recent increase in data on the efficacy and safety of combination treatment with alpha receptor antagonists and antimuscarinic agents, the standard pharmacologic treatment of patients with LUTS combined with OAB should be an alpha receptor antagonist and an antimuscarinic agent. Beta-3 adrenoreceptor agonists may also potentially be useful for the treatment of male LUTS combined with OAB.

show abstract

Overactive bladder in males

Cited by 21 publications

References 89 publications

Inhibition of NMDAR Reduces Bladder Hypertrophy and Improves Bladder Function in Cyclophosphamide Induced Cystitis

Inhibition of NMDAR Reduces Bladder Hypertrophy and Improves Bladder Function in Cyclophosphamide Induced Cystitis

Efficacy of Anticholinergics for Chronic Prostatitis/Chronic Pelvic Pain Syndrome in Young and Middle-Aged Patients: A Single-Blinded, Prospective, Multi-Center Study

Current role of treatment in men with lower urinary tract symptoms combined with overactive bladder

Contact Info

Product

Resources

About